Mark A Lemmon, PhD, FRS
David A. Sackler Professor of Pharmacology; Co-director, Cancer Biology Institute
Departments & Organizations
Pharmacology: Primary Faculty
Yale Cancer Center: Signal Transduction | Yale CTAP
Yale Combined Program in the Biological and Biomedical Sciences (BBS): Biochemistry, Quantitative Biology, Biophysics and Structural Biology (BQBS): Cell Cycle and Signal Transduction; Drug Design, Discovery and Mechanism; Sensory Systems from Molecules to Cells to Organisms | Molecular Medicine, Pharmacology, and Physiology: Cancer Biology and Therapeutics; Structural Biology
Biography
Mark Lemmon, PhD was appointed the Co-Director of the Cancer Biology Institute and the David A. Sackler Professor of Pharmacology in 2015. Dr. Lemmon returns to Yale, where he completed his PhD in 1993, from the University of Pennsylvania’s Perelman School of Medicine. At UPenn, he was the George W. Raiziss Professor of Biochemistry and Biophysics as well as Chair of the department and an Investigator at the Abramson Family Cancer Research Institute. Dr. Lemmon’s research focuses on the signaling pathways of receptor tyrosine kinases (RTKs), which, when mutated cause cancers and other diseases.
Education & Training
| PhD | Yale University (1993) |
|---|---|
| BA | Oxford University (Hertford College), Biochemistry (1988) |
